A Medivation executive at the heart of the company's team that sold the company to Pfizer for $14 billion five years ago is facing allegations of insider trading.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh